Physician profile
Kenneth Dority
NPI 1659313328
$1,969.08
in general payments reported to CMS, 2019-2025
14 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.86 · 2020: $12.85 · 2021: $188 · 2022: $109 · 2023: $350 · 2024: $735 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $570.88 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $251.74 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $168.41 | 2023-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Collegium Pharmaceutical, INC. | $163.64 | 2025 | Jornay Pm |
| Abbvie INC. | $160.29 | 2021-2022 | |
| Neos Therapeutics, LP | $152.55 | 2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $131.08 | 2023-2025 | Xelstrym |
| Alkermes, INC. | $127.20 | 2019-2022 | |
| Noven Pharmaceuticals, INC. | $96.19 | 2023 | Xelstrym |
| Indivior INC. | $75.87 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $22.04 | 2024 | Qelbree |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Axsome Therapeutics, INC. | $15.10 | 2025 | Auvelity |
| Orexo US, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Dority listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.